Institutionalization risk and costs associated with agitation in Alzheimer's disease
Abstract
Agitation in individuals with Alzheimer's disease (AD) may predict institutionalization. This study assessed the incremental risk and costs associated with agitation in individuals with AD.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 01, 2019
- Source ID
- 10.1016/j.trci.2019.10.004
Entities
People
- Ann Hartry
- Annie Guerin
- Keva Gwin
- Marjolaine Gauthier‐loiselle
- Martin Cloutier
- Myrlene Sanon Aigbogun
- Patrick Gagnon‐sanschagrin
- Ross A. Baker
- Ruth Duffy
- The Alzheimer’s Disease Neuroimaging Initiative*
Organizations
- AbbVie
- Alzheimer's Association
- Alzheimer's Disease Neuroimaging Initiative
- Alzheimer's Drug Discovery Foundation
- Analysis Group
- BioClinica
- Biogen
- Bristol-Myers Squibb
- Canadian Institutes of Health Research
- Chiron Corporation
- Eisai
- Eli Lilly and Company
- GE HealthCare
- Hoffmann-La Roche
- Laboratoires Servier
- Lundbeck
- Merck & Co.
- Meso Scale Diagnostics (United States)
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Pfizer
- Roche (United States)
- Takeda Pharmaceutical Company
- United States Department of Defense